Zobrazeno 1 - 10
of 61
pro vyhledávání: '"Matthew A, Marx"'
Publikováno v:
ACS Omega, Vol 7, Iss 36, Pp 32062-32067 (2022)
Externí odkaz:
https://doaj.org/article/bb96fe09f2244a32baee7fd1a9a4530e
Autor:
Jill Hallin, Vickie Bowcut, Andrew Calinisan, David M. Briere, Lauren Hargis, Lars D. Engstrom, Jade Laguer, James Medwid, Darin Vanderpool, Ella Lifset, David Trinh, Natalie Hoffman, Xiaolun Wang, J. David Lawson, Robin J. Gunn, Christopher R. Smith, Nicole C. Thomas, Matthew Martinson, Alex Bergstrom, Francis Sullivan, Karyn Bouhana, Shannon Winski, Leo He, Julio Fernandez-Banet, Adam Pavlicek, Jacob R. Haling, Lisa Rahbaek, Matthew A. Marx, Peter Olson, James G. Christensen
Publikováno v:
Nature Medicine. 28:2171-2182
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d677a7e099fb8459d3aaad7bbf29b468
https://doi.org/10.1038/s41591-022-02007-7
https://doi.org/10.1038/s41591-022-02007-7
Autor:
John M. Ketcham, Jacob Haling, Shilpi Khare, Vickie Bowcut, David M. Briere, Aaron C. Burns, Robin J. Gunn, Anthony Ivetac, Jon Kuehler, Svitlana Kulyk, Jade Laguer, J. David Lawson, Krystal Moya, Natalie Nguyen, Lisa Rahbaek, Barbara Saechao, Christopher R. Smith, Niranjan Sudhakar, Nicole C. Thomas, Laura Vegar, Darin Vanderpool, Xiaolun Wang, Larry Yan, Peter Olson, James G. Christensen, Matthew A. Marx
Publikováno v:
Journal of Medicinal Chemistry. 65:9678-9690
SOS1 is one of the major guanine nucleotide exchange factors that regulates the ability of KRAS to cycle through its "on" and "off" states. Disrupting the SOS1:KRAS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afe52dccfc91d77da8d18ff2be215969
https://doi.org/10.1021/acs.jmedchem.2c00741
https://doi.org/10.1021/acs.jmedchem.2c00741
Autor:
James G. Christensen, Peter Olson, Pasi A. Jänne, Kyriakos P. Papadopoulos, Piro Lito, Sai-Hong Ignatius Ou, Melissa L. Johnson, Igor I. Rybkin, Matthew A. Marx, Douglas P. Cassidy, Emanuel F. Patricoin, Elisa Baldelli, Mariaelena Pierobon, Jeremy Barton, Richard C. Chao, Karen Velastagui, Adam Pavlicek, Julio Fernandez-Banet, Sole Gatto, Yaohua Xue, Guy P. Vigers, John P. Fischer, Jay B. Fell, Michael R. Burkard, Joshua A. Ballard, Brian R. Baer, Vickie Bowcut, Niranjan Sudhakar, David M. Briere, Ruth Aranda, Andrew Calinisan, Lauren Hargis, Lars D. Engstrom, Jill Hallin
Supplementary Composite Figure File
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::095624453d8ad8530fb345958c4cd8b6
https://doi.org/10.1158/2159-8290.22535530.v1
https://doi.org/10.1158/2159-8290.22535530.v1
Autor:
James G. Christensen, Peter Olson, Pasi A. Jänne, Kyriakos P. Papadopoulos, Piro Lito, Sai-Hong Ignatius Ou, Melissa L. Johnson, Igor I. Rybkin, Matthew A. Marx, Douglas P. Cassidy, Emanuel F. Patricoin, Elisa Baldelli, Mariaelena Pierobon, Jeremy Barton, Richard C. Chao, Karen Velastagui, Adam Pavlicek, Julio Fernandez-Banet, Sole Gatto, Yaohua Xue, Guy P. Vigers, John P. Fischer, Jay B. Fell, Michael R. Burkard, Joshua A. Ballard, Brian R. Baer, Vickie Bowcut, Niranjan Sudhakar, David M. Briere, Ruth Aranda, Andrew Calinisan, Lauren Hargis, Lars D. Engstrom, Jill Hallin
Despite decades of research, efforts to directly target KRAS have been challenging. MRTX849 was identified as a potent, selective, and covalent KRASG12C inhibitor that exhibits favorable drug-like properties, selectively modifies mutant cysteine 12 i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dd866fa6fe03bc0849986ce88d5870c4
https://doi.org/10.1158/2159-8290.c.6547879.v1
https://doi.org/10.1158/2159-8290.c.6547879.v1
Autor:
Christopher R. Smith, Ruth Aranda, Thomas P. Bobinski, David M. Briere, Aaron C. Burns, James G. Christensen, Jeffery Clarine, Lars D. Engstrom, Robin J. Gunn, Anthony Ivetac, Ronald Jean-Baptiste, John M. Ketcham, Masakazu Kobayashi, Jon Kuehler, Svitlana Kulyk, J. David Lawson, Krystal Moya, Peter Olson, Lisa Rahbaek, Nicole C. Thomas, Xiaolun Wang, Laura M. Waters, Matthew A. Marx
Publikováno v:
Journal of Medicinal Chemistry. 65:1749-1766
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6807ba018e034c41898a959b92d453dc
https://doi.org/10.1021/acs.jmedchem.1c01900
https://doi.org/10.1021/acs.jmedchem.1c01900
Autor:
Christopher R. Smith, Svitlana Kulyk, Misbha Ud Din Ahmad, Valentina Arkhipova, James G. Christensen, Robin J. Gunn, Anthony Ivetac, John M. Ketcham, Jon Kuehler, J. David Lawson, Nicole C. Thomas, Xiaolun Wang, Matthew A. Marx
Publikováno v:
RSC Medicinal Chemistry. 13:1549-1564
Herein we describe our approach to prioritize five fragment hits with the objective of answering three questions: could the binding potency be improved? Were the series chemically tractable? Could additional co-crystal structures be solved?
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8c927f9ba7684ab99a67e20faf2bf6f
https://doi.org/10.1039/d2md00163b
https://doi.org/10.1039/d2md00163b
Autor:
Xiaolun Wang, Shelley Allen, James F. Blake, Vickie Bowcut, David M. Briere, Andrew Calinisan, Joshua R. Dahlke, Jay B. Fell, John P. Fischer, Robin J. Gunn, Jill Hallin, Jade Laguer, J. David Lawson, James Medwid, Brad Newhouse, Phong Nguyen, Jacob M. O’Leary, Peter Olson, Spencer Pajk, Lisa Rahbaek, Mareli Rodriguez, Christopher R. Smith, Tony P. Tang, Nicole C. Thomas, Darin Vanderpool, Guy P. Vigers, James G. Christensen, Matthew A. Marx
Publikováno v:
Journal of Medicinal Chemistry. 65:3123-3133
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0a806650aaec5c7d35ae8ff6555c3535
https://doi.org/10.1021/acs.jmedchem.1c01688
https://doi.org/10.1021/acs.jmedchem.1c01688
Autor:
Christopher R. Smith, Ruth Aranda, James G. Christensen, Lars D. Engstrom, Robin J. Gunn, Anthony Ivetac, John M. Ketcham, Jon Kuehler, J. David Lawson, Matthew A. Marx, Peter Olson, Nicole C. Thomas, Xiaolun Wang, Laura M. Waters, Svitlana Kulyk
Publikováno v:
Bioorganicmedicinal chemistry. 71
MRTX1719 is an inhibitor of the PRMT5/MTA complex and recently entered clinical trials for the treatment of MTAP-deleted cancers. MRTX1719 is a class 3 atropisomeric compound that requires a chiral synthesis or a chiral separation step in its prepara
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50d8dc89ffc4b87f35f5c33212dddbbe
https://pubmed.ncbi.nlm.nih.gov/35926325
https://pubmed.ncbi.nlm.nih.gov/35926325
Autor:
Laura Vegar, Ruth Aranda, Laura Waters, Krystal Moya, Allan Hebbert, Christopher S. Smith, Jill Hallin, Briere M. David, Lars D. Engstrom, Darin Vanderpool, Matthew M. Marx, James G. Christensen, Peter A. Olson
Publikováno v:
Cancer Research. 83:2778-2778
Previous studies have shown that cancer cell lines with homozygous deletion of the MTAP gene (MTAP del), are selectively sensitive to shRNA-mediated PRMT5 inhibition or MTA-cooperative PRMT5 inhibitors. PRMT5 is a methyltransferase that adds symmetri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::59a5f74b265f347e3c00714aa45465b9
https://doi.org/10.1158/1538-7445.am2023-2778
https://doi.org/10.1158/1538-7445.am2023-2778